Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 2/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | TTK | P33981 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.30 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.30 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.30 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6926441 | 0.80 | CLK1 (0.36) | — | |
| SCHEMBL678622 | 0.78 | KIF11 (0.61) | KIF11CHEK1KMT2AMEN1TTK | |
| SCHEMBL2855389 | 0.69 | CLK1 (0.51) | — | |
| SCHEMBL6924704 | 0.68 | KIF11 (0.51) | KIF11TTKMAPT | |
| SCHEMBL29951311 | 0.68 | KIF11 (0.51) | KIF11TTKMAPT | |
| SCHEMBL1849463 | 0.64 | MAPT (0.49) | CHEK1MAPTAURKAPARP1GABRA1 | |
| SCHEMBL675117 | 0.63 | KIF11 (0.51) | KIF11CHEK1MAPTAURKA | |
| SCHEMBL6925164 | 0.62 | KIF11 (0.63) | KIF11TTKAURKAPARP1GABRA1 | |
| SCHEMBL679342 | 0.62 | TLR4 (0.51) | CHEK1MAPT | |
| SCHEMBL4428308 | 0.62 | KIF11 (0.50) | KIF11KMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030203901-A1 | Methods of modulating tyrosine protein kinase function with indolinone compounds | SUGEN, INC. | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203901-A1 | Methods of modulating tyrosine protein kinase function with indolinone compounds | LCK, ABL1, PNCK | KIF11 3404/4885CHEK1 598/4885KMT2A 1912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.